Apex Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Apex Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$497K	Sell	6,021 -546	-8%	-$44.4K	0.01%	232
2015 Q4	$688K	Buy	6,567 +2,510	+62%	+$262K	0.02%	193
2015 Q3	$427K	Sell	4,057 -3,474	-46%	-$464K	0.01%	224
2015 Q2	$1.03M	Buy	7,531 +5,912	+365%	+$733K	0.02%	183
2015 Q1	$202K	Buy	+1,619	New	+$172K	﹤0.01%	246

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Apex Capital Management's BMRN Position: Q1 2016 in Review

Apex Capital Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.3% in Q1 2016, selling an estimated $44.4K and leaving 6,021 shares worth $497K. The position accounts for 0.01% of the portfolio, ranked #232.

Apex Capital Management first reported a position in BMRN in Q1 2015 and has held it in 5 quarters since. The position peaked at $1.03M in Q2 2015. 391 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Apex Capital Management held 6,021 shares of BioMarin Pharmaceuticals worth $497K as of Q1 2016.
Apex Capital Management sold 546 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $44.4K.
BioMarin Pharmaceuticals made up 0.01% of Apex Capital Management's portfolio in Q1 2016, its #232 holding.
Apex Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 5 quarters since.
Apex Capital Management's BioMarin Pharmaceuticals position peaked at $1.03M in Q2 2015.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.